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Abstract
Purpose—Current investigational priorities in the treatment of favorable histology Wilms tumor 
(FHWT) center on accurate staging and risk-stratification. The extent of lymph node (LN) 
sampling has not been clearly defined; its importance cannot be overstated as it guides adjuvant 
therapy. The identification of a minimum LN yield to minimize the risk of harboring occult 
metastatic disease could help development of surgical guidelines. This study focuses on using the 
beta-binomial distribution to estimate the risk of occult metastatic disease in patients with FHWT.
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Materials & methods—The National Cancer Database was queried for patients with unilateral 
FHWT from 2004 to 2013. Data were used to characterize nodal positivity for patients who 
underwent surgery and had ≥1 positive LN and ≥2 LNs examined. The probability of missing a 
positive LN (i.e., false negative) for a given LN yield was calculated using an empirical estimation 
and the beta-binomial model. Patients were then stratified by tumor size.
Results—422 patients met study criteria. To limit the chance of missing a positive LN to ≤10%, 
the empirical estimation and beta-binomialmodel estimated that 6 and 10 LNs needed to be 
sampled, respectively. Tumor size did not influence the result. Internal validation showed little 
variation to maintain a false negative rate ≤ 10%.
Conclusions—Using mathematical modeling, it appears that the desired LN yield in FHWT to 
reduce the risk of false-negative LN sampling to ≤10% is between 6 and 10. The current analysis 
represents an objective attempt to determine the desired surgical approach to LN sampling to 
accurately stage patients with FHWT.
Level of evidence—II
Keywords
Wilms tumor; Nephroblastoma; Lymph node; Survival
As survival for patients with Favorable histology (FH) Wilms tumor (WT) has improved 
dramatically [1], current investigational priorities center on risk-stratification [2]. This 
involves selection of which patients can avoid treatment-intensification without sacrificing 
excellent outcomes [3]. Conversely, stratification should accurately select patients who 
require more intense regimens. The importance of lymph node (LN) sampling in stratifying 
WT cannot be overstated, as it affects staging and thus adjuvant therapy. However, concerns 
exist about the accuracy of LN sampling as currently practiced.
This issue is not unique to WT. Previous investigation into patients with thyroid cancer 
suggests that a limited LN examination is a risk for harboring occult metastatic disease [4]. 
Using statistical modeling and National Cancer Database (NCDB) data, specific LN yield 
thresholds were calculated to quantify the probability of missing nodal disease. Similarly, 
this approach with modeling NCDB data has been used to assess LN thresholds for colon 
cancer [5]. Given a desire to more accurately risk-stratify patients with FHWT and the 
background of similar studies for thyroid and colon cancers [4], the objective of the current 
study is to quantify the risk of missing nodal disease based on LN yields, thus identifying a 
threshold LN yield that can minimize the false-negative rate of LN sampling. Specifically, 
how many LNs must be sampled to reduce the chance that a positive LN is missed to below 
10%, assuming that a positive LN exists. The potential for a specific nodal yield threshold to 
change staging, followed by receipt of stage-guided adjuvant therapy and thus potentially 
outcomes, is the critical importance of this study.
1. Materials & methods
The NCDB was reviewed to identify the study population. All data obtained from the NCDB 
are deidentified and IRB exemption was obtained. This study was modeled after that of 
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Robinson et al. [4], which focused on the adequacy of LN sampling in patients with thyroid 
cancer, also utilizing NCDB data.
1.1. Study population
Data on patients with WT between 2004 and 13 (n = 3669) were obtained. Patient records 
with unknown follow-up, unknown treatment, no LN sampling or unknown LN yield, 
bilateral disease and unfavourable histology were excluded (n = 1544). Additionally, patients 
without involved LNs (n = 1369), those with ≪2 LNs sampled (n = 57), or both (n = 277) 
were excluded. This resulted in a population of 422 patients surgically managed for 
unilateral FHWT who had ≥2 LNs sampled, had ≥1 LN involved and had detailed count 
information available about LN sampling. LN yield was defined as the number of LNs 
surgically obtained and evaluated by pathology.
Specifically, to determine the probability that a positive LN was missed during LN sampling, 
the analysis was limited to patients with LN involvement. For patients without LN 
involvement, it was not possible to determine whether there was truly no nodal involvement 
or whether occult disease may have existed but was missed owing to limited LN sampling. 
This is the key reasoning behind restricting the analysis to those with positive LNs.
1.2. Data analysis
Statistical analyses were performed using R (v.3.4.1) statistical software package. For the 
purposes of this study, it was decided a priori that a probability of missing a positive LN of 
≤10%, or a false-negative LN sampling rate of ≤10%, was acceptable [4,5]. While the 
primary focus was to determine the LN yield to keep the probability of missing a positive 
LN to ≤10%, other false-negative rates (≤5% and ≤ 15%)were examined. Importantly, the 
false negative ratewas determined by identifying the rate at which 90% of true positive 
patients would be correctly identified, with the remaining 10% of true positives being 
missed (false negative).
A binomial distribution could be used to model the number of positive LN for a given LN 
yield. However, the LN positivity rate is fixed in the binomial model and assumes the same 
LN positivity rate for all patients, which is unlikely owing to intrinsic heterogeneity of the 
patient population. Instead of using a fixed LN positivity rate, the beta-binomial distribution 
could be used instead as this model allows the LN positivity rate to vary across patients 
(Vector Generalized Linear and Additive Models package in R). The beta-binomial model 
was ultimately chosen because it allows the LN positivity rate to vary across patients, which 
is a more realistic assumption. Additionally, this approach has been used in recent studies 
[4,5] similar to this one.
Empirical calculations were also included based on the binomial model to serve as a 
sensitivity analysis for the beta-binomial model. For the empirical approach, the rate of LN 
positivity was averaged based on the entire cohort (i.e. total number of positive LNs divided 
by the total LN yield). The binomial model was then used to determine the false-negative 
rate for a given LN yield. Given that the empirical approach uses a fixed rate that is applied 
to the entire population, it must be noted that the variance will be underestimated and thus 
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results will be biased toward underestimating the yield needed for a given false-negative 
rate.
Internal validation was conducted on the beta-binomial model where subjects were 
randomly resampled with replacement using bootstrap resampling 1000 times to assess the 
variability in the LN yield needed to maintain a false negative rate of ≤10%. The mean and 
estimated 95% CI (using the Interquartile Range (IQR)) were obtained from the bootstrap 
samples. In addition, patients were stratified by tumor size to determine if size changed the 
probability of missing a positiveLN.
2. Results
422 patients met inclusion criteria (Table 1). Tumor size information was missing for some 
and therefore the sample size was slightly reduced (n=398) when evaluating the effect of 
size on LN yield threshold. All patients included had positive LNs, thus local stage III, so 
each one should have received chemotherapy and radiation therapy per protocol. However, 
as presented in Table 1, it is clear that not all patients were treated per protocol (7.6% 
without chemotherapy, 10.4% without radiation).
Two model parameters were estimated from the data for the beta-binomial model, μ = 0.39 
(IQR 0.36–0.42) and ρ = 0.22 (IQR 0.18–0.26). The interpretation for the estimated mean 
(μ) of 0.39 is that, on average, for each patient a positive LN was found 39% of the time. 
This was found to be 33% using the empirical approach. The interpretation of ρ is the 
correlation between the LNs sampled within an individual. Table 2 summarizes the false 
negative probability as a function of LN yield for both models. For the beta-binomial model, 
an LN yield of 10 LNs lowered the probability of missing a positive LN to 10% and for the 
empirical estimation, this LN yield threshold was 6 LNs. Comparing the most common LN 
yield of 2 (mode, Table 1) vs. an LN yield of 10, using the beta-binomial model, the rate of 
false negative sampling is 42% and 10%, respectively (Table 2). This suggests that if the 
most common LN yield of 2 was increased to 10 it will be possible to reduce the number of 
incorrectly staged patients by 30%. Comparing the median LN yield of 6 vs. an LN yield of 
10, using the beta-binomial model, the rate of false negative sampling is 17% and 10%, 
respectively (Table 2). This suggests that if the median LN yield of 6 was increased to 10, 
approximately 7% of patients would have a change in stage. This is presented graphically for 
the overall population and stratified by tumor size (Fig. 1 and Fig. 2). Stratification by tumor 
size did not appear to affect the false-negative rate. Furthermore, internal validation 
(bootstrapping) of the beta-binomial model demonstrated little variation in the LN yield 
needed to maintain a false negative rate ≤ 10%, with an interquartile range (IQR) of 9–12 
LNs.
To reduce the probability of missing a positive LN below 5 and 15%, LN yields of 18 and 7 
(beta-binomial model) and 8 and 5 (empirical estimation) were identified.
3. Discussion
Lack of LN sampling represents the most frequent surgical protocol deviation inWT [6], and 
has been observed in numerous studies to impact survival, likely through understaging and 
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inadequate administration of stage-directed adjuvant therapy [7,8]. Factors that result in 
local stage III designation (LN involvement, tumor spillage, preoperative biopsy, and local 
residual disease) have all been independently associated with worse survival and thus, such 
patients are managed with additional adjuvant therapies (radiation and doxorubicin) [2]. 
While excellent survival can still be achieved, there are increased toxicities associatedwith 
intensified therapy [9].Not all stage III patients experience the same outcome. LN positivity 
is associatedwith lower event free survival than the other factors [2,10]. This emphasizes the 
importance of adequate LN sampling to accurately characterize LN involvement. This study 
provides the first estimate of potential stage change based on LN yield, specifically that 30% 
of patients may be identified as having occult LN involvement when comparing an LN yield 
of 2 (most common LN yield in this cohort; estimated 42% false-negative rate) to 10 
(estimated 10% false-negative rate). The clinical implications of this potential understaging 
are unknown, but this risk may now be quantified and perhaps can be studied in the future as 
it relates to relapse in stage I/II patients. If these results are extended to patients excluded 
from the analysis (n= 1703) because the LN sampling was omitted or had≪2 LNs sampled, 
86% had an LN yield≪10, and thus a large proportion of patients had a high potential of 
being inadequately staged.
It is well-reported that LN yield is generally higher in patients with LN positive disease and 
unfavorable histology, possibly owing to surgeon bias during the nephrectomy [8,11]. In 
contrast, prior work also demonstrates that surgeons are not reliably able to predict whether 
LNs are grossly involved [8]. Surgical factors affecting LN yield are important to highlight, 
as these are modifiable. To determine what drives LN yield, human decision-making should 
be minimized, and this likely requires a minimal LN yield goal. It could be argued that 
removing as many LNs as possible is a strategy to accurately determine LN involvement. 
However, Kieran et al. [8] observed that LN yield in stage I and II WT did not predict event 
free survival. So while simply increasing the LN yield ad infinitum does not appear to confer 
any benefit, data do indicate that the ratio of positive LNs to the LN yield may predict 
survival [12]. The clinical importance of LN sampling lies in its ability to accurately reflect 
LN involvement, and perhaps could be used to measure surgical standardization.
Based on visual inspection of the histograms of their data alone, Kieran et al. [8] reported 
that LN positivity increases proportionally with LN yield and that an LN yield ≥7 would be 
optimal. The methodology used in this prior work was essentially an empirical estimation 
using a universal LN positivity rate, which was verified by the present study. The current 
study provides a more robust estimate for an LN yield cutoff since it allows the LN 
positivity rate to vary across patients, reducing bias when compared to the empirical 
approach. There are several important differences between the study of Kieran et al. [8] and 
the one reported herein that warrant discussion. Their study [8] had three primary outcomes; 
one was to determine if LN yield predicted event-free survival in patients with unilateral, 
nonmetastatic WT using data from NWTS-4/5. A difference was not observed, but the 
information gathered was extrapolated to determine a minimal LN yield threshold to ensure 
“accurate staging”, which was not explicitly defined as it was not a primary study objective. 
The rate of LN positivity was calculated for various LN yields, with LN positivity reaching a 
plateau around 28% when 7 LNs are sampled. The correlating false negative rate of 7 LNs 
was 15% in the present study. This method of identifying a threshold is based on visual 
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inspection of a histogram and is thus very descriptive in nature. The current study’s 
modeling approach provides a more accurate and objective estimate of the LN yield as it 
relates to the false negative rate. Additional differences were that the prior study included 
stage I and II patients, who, by definition do not have LNs involved, and the previously 
demonstrated relationship of LN yield and LN positivity was not accounted for [8,11]. In the 
current study, NCDB data were used and analysis was restricted to those who had involved 
LNs. This method of establishing an LN threshold provides a more objective assessment and 
accounts for the interaction of LN yield and positivity. The beta-binomial model provides a 
means to identify the number of LNs that must be sampled to keep the risk of occult nodal 
disease below a threshold.
In an attempt to verify the findings of the beta-binomial model, empirical calculations were 
also performed. Empirical probability tends to underestimate the LN yield threshold because 
it does not account for the correlation between the existence of a positive node and the 
number of nodes that were sampled for an individual. As expected, the threshold using 
empirical calculations (≥6 LNs) was slightly less than with that of the beta-binomial model 
(≥10 LNs). However, the lack of external validation is a study limitation. At the very least, 
the internal validation from bootstrapping suggests that the LN yield thresholds identified 
are stable as they did not change significantly across 1000 bootstrap samples.
When considering the implication of utilizing such an LN threshold, it is important to 
balance potential benefit versus harm in applying this threshold. For those with occult LN 
disease, it potentially reduces the chance of missing the involved LN and the associated 
stage change. As for harm, there is theoretically an increased risk of chylous ascites. 
Fortunately, this is an uncommon complication as reported by 2 publications. An NWTS-4 
review identified a single case of chylous ascites in 534 randomly sampled patients (0.2%). 
This is lower than rates of splenic or diaphragmatic or pancreatic injury [12]. There is also a 
single institution report of 3 cases of chylous ascites in 80 resections for WT (3.75%). When 
combining these cases with those reported from NWTS-3/4, there were 9 cases, including 1 
where LNs were not sampled [13]. Overall, the authors feel that the low incidence of 
chylous ascites in this population is worth the benefit of increasing the goal LN yield to 
reduce mis-staging.
Reports from a wide-variety of solid tumors indicate that advanced metrics in assessing LN 
positivity can serve as useful prognostic markers [11,14–23]. LN density, number of 
involved LNs/LN yield, specifically has been demonstrated to predict disease recurrence and 
survival in multiple malignancies [4,15–22], and most relevant to the current study, in 
FHWT [11]. However, a major limitation of the interpretation and applicability of LN 
density for WT patients is a lack of standardized guidelines for what constitutes LN 
sampling. Thus, LN yield, the denominator, can vary widely, making any conclusions 
involving LN yield limited. Using the findings from the present series, the identification of 
an LN yield threshold could be used to standardize LN sampling. The extent of LN 
sampling, as well as the location of LN sampling, must be better defined to further study and 
understand how this specific element of WT treatment impacts outcomes. This is a major 
limitation of the NCDB as the extent or location of LNs sampled cannot be determined. 
However, given the restrictions of funding and general availability of data from NWTS, 
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COG and SIOP cohorts, the NCDB is the next best (and largest) available dataset with 
patients to study. Even data from NWTS and COG do not record extent or location of LN 
sampling, so these data may serve as a call to again reemphasize the importance of 
standardizing LN sampling in all cases. Also, it should encourage prospective study of this 
issue, likely through surgical templates and/or protocols, to validate the findings of this 
study.
The present study comes with several other limitations. Data from an administrative dataset 
come with inherent limitations, such as missing values and reporting and selection bias. It 
was not designed for this study and allows only secondary analysis. For this study 
specifically, it is understood that LN yield depends on many factors which may not be able 
to be accounted for in the NCDB, or any database for that matter. For example, the 
experience from colorectal cancer has demonstrated that patient, surgeon, and pathologist-
specific factors impact nodal yield [24–26]. Additionally, there are data to support that 
specimen designation (en-bloc resection with the kidney vs. separate specimen) can 
influence the LN yield [27]. It is possible that surgeons contributing to this database may 
report higher LN yields owing to his/her performance of more extended LN sampling. Also, 
in this specific disease, the AJCC staging (captured by NCDB) is slightly different than the 
COG staging system used clinically and the NCDB does not include timing of chemotherapy 
or radiation therapy administration (neoadjuvant vs. adjuvant). Additionally, as pointed out 
by previous studies, several assumptions were made to determine the false-negative rate 
using the beta-binomial model [4,5]. First is the assumption that there were no false-
positives. Second, all LNs sampled have the same probability of being involved. Third, the 
sensitivity is the same between true positives and false negatives. These assumptions allowed 
us to generalize the results to all FHWT patients, including node negative individuals. Since 
the analysis was limited to only individuals that were node positive, our results may be 
biased toward a more conservative estimate, which may be justified since assessing slightly 
more LNs than needed likely offers minimal increased patient risk, while the chance of 
missing metastatic disease may have more patient risk. Lastly, to generalize these results, it 
is assumed that the patients studied here are representative of the general population with 
FHWT.
4. Conclusion
This is an objective attempt to determine the desired LN yield to accurately stage patients 
with FHWT, and it is suggested from these data that by standardizing LN sampling patterns 
and emphasizing the clinical importance of appropriate LN sampling, the risk of a false-
negative LN sampling can be reduced in order to more accurately risk-stratify these patients. 
These data may be used to standardize future surgical guidelines.
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Fig. 1. 
The beta-binomial model probability of a false-negative LN sampling as a function of LN 
yield. Results for the entire patient population (red line) as well as stratification by tumor 
size are shown. Dashed gray lines indicate the minimum LN yield needed to reach a false-
negative rate ≤10%.
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Fig. 2. 
The empirical probability of a false-negative LN sampling as a function of LN yield. Results 
for the entire patient population (red line) as well as stratification by tumor size are shown. 
Dashed gray lines indicate the minimum LN yield needed to reach a false-negative rate 
≤10%.
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Table 1
OverView of the NCDB dataset used to assess lymph nodes for patients with FHWT.a
All Patients (N = 422)
Patient Age, years (median [IQR]) 3 [2–5]
Sex [N (%)]
Male 188 (44.5)
Female 234 (55.5)
Race [N (%)]
White 326 (79.3)
Black 64 (15.6)
Other 21 (5.1)
Insurance [N (%)]
Private 246 (60.6)
Government 146 (36.0)
Uninsured 14 (3.4)
Laterality [N (%)]
Right 178 (42.2)
Left 244 (57.8)
LN Yield (mode) 2
LN Yield (median [IQR]) 6 [3–11]
Number of Positive LNs (median [IQR]) 2 [1–3]
LN Density (median [IQR]) 0.33 [0.17–0.53]
Tumor Size, cm (median [IQR]) 11.55 [9–14]
Overall Tumor Stage [N (%)]
3 66 (48.5)
4 70 (51.5)
Any Chemotherapy Use [N (%)]
No 32 (7.6)
Yes 390 (92.4)
Any Radiation Use [N (%)]
No 44 (10.4)
Yes 378 (89.6)
a
Median LN Yield was 3 (range 0–87, IQR 5) for the NCDB dataset of all patients with FHWT meeting the same study criteria but including LN 
negative patients [11].
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